Oncopeptides AB (publ) (STO: ONCO)
Sweden
· Delayed Price · Currency is SEK 2.210
+0.035 (1.61%)
Aug 30, 2024, 5:29 PM CET
Oncopeptides AB Company Description
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally.
Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients.
The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors.
Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Oncopeptides AB (publ)
| Country | Sweden |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Sofia Heigis |
Contact Details
Address: Luntmakargatan 46 Stockholm, 111 37 Sweden | |
| Phone | 46 86 15 20 40 |
| Website | oncopeptides.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009414576 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sofia Heigis M.Sc. | Chief Executive Officer |
| Dr. Jakob Lindberg Med. Lic | Chief Scientific Officer |
| Prof. Rolf Larsson M.D., Ph.D. | Founder |
| Prof. Rolf Lewensohn M.D., Ph.D. | Founder |
| Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. | Founder |
| Dr. Kristina Luthman Ph.D. | Founder |
| Prof. Hans Ehrsson M.D. | Founder |
| Peter Nygren | Founder |
| Henrik Bergentoft | Chief Financial Officer |
| Eva Nordström M.Sc., MSc Pharm | Chief Operating Officer and Deputy MD |